Skip to main content

16-02-2018 | Prostate cancer | News | Article


Abiraterone acetate approved for metastatic castration-sensitive prostate cancer

medwireNews: US men with metastatic, high-risk castration-sensitive prostate cancer may now be prescribed abiraterone acetate in combination with prednisone following FDA approval of the strategy.

The announcement is based on findings from the LATITUDE trial, demonstrating improved overall survival with the androgen receptor inhibitor plus prednisone versus placebo, as well as a significantly longer time to initiation of chemotherapy.

Abiraterone acetate plus prednisone previously received FDA approval for the treatment of metastatic castration-resistant prostate cancer following chemotherapy and later as a first-line approach for this indication.

The recommended dose for metastatic castration-sensitive prostate cancer is 1000 mg/day plus prednisone 5 mg/day, alongside gonatrophin-releasing hormone analog therapy or bilateral orchiectomy.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also: